Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

599

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Dry Eye Disease (DED)
Interventions
DRUG

NOV03

100% Perfluorohexyloctane

DRUG

Placebo

Saline solution (0.6% sodium chloride solution)

Trial Locations (29)

12159

Bausch Site 128, Slingerlands

16066

Bausch Site 122, Cranberry Township

27603

Bausch Site 114, Raleigh

32256

Bausch Site 115, Jacksonville

33603

Bausch Site 117, Tampa

33773

Bausch Site 106, Largo

33901

Bausch Site 129, Fort Myers

35233

Bausch Site 124, Birmingham

37205

Bausch Site 109, Nashville

38119

Bausch Site 107, Memphis

41017

Bausch Site 119, Edgewood

46260

Bausch Site 112, Indianapolis

60046

Bausch Site 108, Lake Villa

63131

Bausch Site 111, St Louis

64111

Bausch Site 113, Kansas City

78229

Bausch Site 118, San Antonio

78681

Bausch Site 105, Round Rock

78738

Bausch Site 104, Lakeway

79902

Bausch Site 120, El Paso

85254

Bausch Site 125, Scottsdale

90505

103, Torrance

Bausch Site 123, Torrance

90805

Bausch Site 121, Long Beach

91204

Bausch Site 110, Glendale

91345

Bausch Site 102, Mission Hills

92663

Bausch Site 101, Newport Beach

95670

Bausch Site 116, Rancho Cordova

06810

Bausch Site 127, Danbury

01890

Bausch Site 126, Winchester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT04139798 - Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) | Biotech Hunter | Biotech Hunter